FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169387631> ?p ?o ?g. }

• W2169387631 abstract "We have previously demonstrated that prolonged treatments with raloxifene (RAL) in vitro will result in phase II RAL resistance and RAL-induced tumor growth. Clinical interest prompted us to re-examine RAL resistance in vivo, particularly the effects of long-term treatments (a decade or more) on the evolution of RAL resistance. In this study, we have addressed the question of this being a reproducible phenomenon in wild-type estrogen receptor (ER)-positive human breast cell line MCF-7. MCF-7 cells cultured under estrogen-deprived conditions in the presence of 1 microM RAL for more than a year develop RAL resistance resulting in an independent cell line, MCF7-RAL. The MCF7-RAL cells grow in response to both estradiol E2 and RAL. Fulvestrant (FUL) blocks RAL and E2-mediated growth. Transplantation of MCF7-RAL cells into athymic ovariectomized mice and treatment with physiologic doses of E2 causes early E2-stimulated tumor growth. In contrast, continuous treatment of implanted animals with daily oral RAL (1.5 mg daily) causes growth of small tumors within 15 weeks. Continuous re-transplantation of the tumors growing in RAL-treated mice indicated that RAL stimulated tumor growth. Tumors in the untreated mice did not grow. Bi-transplantation of MCF7-E2 and MCF7-RAL tumors into the opposing mammary fat pads of the same ovariectomized animal demonstrated that MCF7-E2 grew with E2 stimulation and not with RAL. Conversely, MCF7-RAL tumors grew with RAL and not E2, a characteristic of phase II resistance. Established phase II resistance of MCF7-RAL tumors was confirmed following up to 7 years of serial transplantation in RAL-treated athymic mice. The ERalpha was retained in these tumors. The cyclical nature of RAL resistance was confirmed and extended during a 2-year evolution of the resistant phases of the MCF7-RAL tumors. The MCF7-RAL tumors that initially were inhibited by E2 grew in the presence of E2 and subsequently grew with either RAL or E2. RAL remained the major grow stimulus and RAL enhanced E2-stimulated growth. Subsequent transplantation of E2 stimulated tumors and evaluations of the actions of RAL, demonstrated robust E2-stimulated growth that was blocked by RAL. These are the characteristics of the anti-estrogenic actions of RAL on E2-stimulated breast cancer growth with a minor component of phase I RAL resistance. Continuous transplantation of the phase I RAL-stimulated tumors for >8 months causes reversion to phase II resistance. These data and literature reports of the cyclical nature of anti-androgen/androgen responsiveness of prostate cancer growth, illustrate the generality of the evolution of anti-hormonal resistance in sex steroid-sensitive target tissues." @default.
• W2169387631 created "2016-06-24" @default.
• W2169387631 creator A5005756055 @default.
• W2169387631 creator A5011080677 @default.
• W2169387631 creator A5032933031 @default.
• W2169387631 creator A5034518910 @default.
• W2169387631 creator A5037103180 @default.
• W2169387631 creator A5037295746 @default.
• W2169387631 creator A5048218662 @default.
• W2169387631 creator A5051526729 @default.
• W2169387631 creator A5054386908 @default.
• W2169387631 creator A5065051726 @default.
• W2169387631 creator A5070591384 @default.
• W2169387631 creator A5073116324 @default.
• W2169387631 date "2010-08-01" @default.
• W2169387631 modified "2023-10-17" @default.
• W2169387631 title "Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance." @default.
• W2169387631 cites W1495332006 @default.
• W2169387631 cites W1520764408 @default.
• W2169387631 cites W1562190372 @default.
• W2169387631 cites W1767522526 @default.
• W2169387631 cites W188120159 @default.
• W2169387631 cites W1944448503 @default.
• W2169387631 cites W1965041083 @default.
• W2169387631 cites W1966538470 @default.
• W2169387631 cites W1974628872 @default.
• W2169387631 cites W1976709816 @default.
• W2169387631 cites W1976732293 @default.
• W2169387631 cites W1977779461 @default.
• W2169387631 cites W1980757374 @default.
• W2169387631 cites W2001652125 @default.
• W2169387631 cites W2007007521 @default.
• W2169387631 cites W2048257551 @default.
• W2169387631 cites W2051390008 @default.
• W2169387631 cites W2051676088 @default.
• W2169387631 cites W2051967652 @default.
• W2169387631 cites W2056830390 @default.
• W2169387631 cites W2061023819 @default.
• W2169387631 cites W2075837694 @default.
• W2169387631 cites W2078885070 @default.
• W2169387631 cites W2083251326 @default.
• W2169387631 cites W2088902203 @default.
• W2169387631 cites W2092037135 @default.
• W2169387631 cites W2104139848 @default.
• W2169387631 cites W2105883471 @default.
• W2169387631 cites W2106841768 @default.
• W2169387631 cites W2107277218 @default.
• W2169387631 cites W2107859602 @default.
• W2169387631 cites W2111328291 @default.
• W2169387631 cites W2111563292 @default.
• W2169387631 cites W2112629831 @default.
• W2169387631 cites W2115103771 @default.
• W2169387631 cites W2125324517 @default.
• W2169387631 cites W2137695810 @default.
• W2169387631 cites W2137920359 @default.
• W2169387631 cites W2139119349 @default.
• W2169387631 cites W2140276460 @default.
• W2169387631 cites W2140794979 @default.
• W2169387631 cites W2141647078 @default.
• W2169387631 cites W2142264022 @default.
• W2169387631 cites W2150593943 @default.
• W2169387631 cites W2152485630 @default.
• W2169387631 cites W2155445409 @default.
• W2169387631 cites W2158038535 @default.
• W2169387631 cites W2160584021 @default.
• W2169387631 cites W2166760402 @default.
• W2169387631 cites W2167399292 @default.
• W2169387631 cites W2171260495 @default.
• W2169387631 cites W2990406756 @default.
• W2169387631 cites W2408396075 @default.
• W2169387631 doi "https://doi.org/10.3892/ijo_00000687" @default.
• W2169387631 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3023309" @default.
• W2169387631 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20596666" @default.
• W2169387631 hasPublicationYear "2010" @default.
• W2169387631 type Work @default.
• W2169387631 sameAs 2169387631 @default.
• W2169387631 citedByCount "9" @default.
• W2169387631 countsByYear W21693876312012 @default.
• W2169387631 countsByYear W21693876312013 @default.
• W2169387631 countsByYear W21693876312014 @default.
• W2169387631 countsByYear W21693876312015 @default.
• W2169387631 countsByYear W21693876312016 @default.
• W2169387631 countsByYear W21693876312019 @default.
• W2169387631 countsByYear W21693876312022 @default.
• W2169387631 crossrefType "journal-article" @default.
• W2169387631 hasAuthorship W2169387631A5005756055 @default.
• W2169387631 hasAuthorship W2169387631A5011080677 @default.
• W2169387631 hasAuthorship W2169387631A5032933031 @default.
• W2169387631 hasAuthorship W2169387631A5034518910 @default.
• W2169387631 hasAuthorship W2169387631A5037103180 @default.
• W2169387631 hasAuthorship W2169387631A5037295746 @default.
• W2169387631 hasAuthorship W2169387631A5048218662 @default.
• W2169387631 hasAuthorship W2169387631A5051526729 @default.
• W2169387631 hasAuthorship W2169387631A5054386908 @default.
• W2169387631 hasAuthorship W2169387631A5065051726 @default.
• W2169387631 hasAuthorship W2169387631A5070591384 @default.
• W2169387631 hasAuthorship W2169387631A5073116324 @default.
• W2169387631 hasConcept C121608353 @default.
• W2169387631 hasConcept C126322002 @default.
• W2169387631 hasConcept C134018914 @default.

• next